Recruiting

Y-90 Radioembolization

Sponsor:

Palo Alto Veterans Institute for Research

Code:

NCT07303712

Conditions

Hepatocellular Carcinoma (HCC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).

Conditions

Hepatocellular Carcinoma (HCC)

Study ID

NCT07303712

Start date

Aug 1, 2024

Status verified date

Oct, 2025

Completion date

Dec 1, 2026

Anticipated

Primary completion date

Aug 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Age > or = 18 years
2. HCC confirmed on imaging, BCLC stage 0, A, B, or C
3. Transarterial Y90 radioembolization approved by multidisciplinary tumor board -

Exclusion Criteria:

1. Not eligible for Y90 procedure
2. Prior surgery or ablation on indicated tumors
3. Patient unable to complete the follow up visits required for clinical care or research -

Study Design

Enrollment

12 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Circulating Tumor Cell (CTC) [ Time Frame: Baseline, 1 month post treatment, 3 months post treatment, and 6 months post treatment ]
  • CTA imaging [ Time Frame: Baseline, 3 months post treatment, 6 months post treatment ]

Central Contacts and Locations

Central contacts

Sirish Kishore, MD

650-493-5000sirish.kishore@va.gov

Luisa Manfredi, MPH

650-493-5000luisa.manfredi1@va.gov

Locations

VA Palo Alto Health Care System

Recruiting

Palo Alto, California, United States, 94304

Contacts

Sirish Kishore, MD

650-493-5000

More Information

Sponsor

Palo Alto Veterans Institute for Research

Last update posted

Dec 26, 2025

Last verified

Oct, 2025

Keywords

  • Circulating tumor cell (CTC)
  • y90

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Palo Alto Veterans Institute for Research on 2025-12-26.